Suzhou Kanger Biomedical

Suzhou Kanger Pharmaceutical is a clinical-stage biotechnology company headquartered in the Suzhou Industrial Park, China. The company is dedicated to the research and development of innovative small molecule drugs, with a primary focus on metabolic disorders such as type 2 diabetes and hyperuricemia. Its lead clinical candidate, KE-101, is a GPR119 agonist currently being evaluated for its potential to improve glycemic control and metabolic health. Additionally, the company is developing KE-301, a potent URAT1 inhibitor designed to treat gout by promoting uric acid excretion. Suzhou Kanger aims to provide high-quality, affordable therapeutic solutions for patients worldwide through its integrated drug discovery and development capabilities.